Key result
Iatrogenic atrial septal defect closure after transseptal mitral valve interventions was associated with 94% survival at 30 days and 71% survival at 12 months.
Why the study?
Indications for closure and outcomes of iatrogenic atrial septal defects after transseptal mitral valve interventions had not been reported.
What are the indications and clinical outcomes for transcatheter iatrogenic atrial septal defect closure after transseptal mitral valve interventions?
Cohort (n=17)
No
What are the indications and clinical outcomes for transcatheter iatrogenic atrial septal defect closure after transseptal mitral valve interventions?
Transcatheter closure of iatrogenic ASDs after transseptal mitral valve interventions is safe with low 30-day mortality, though 1-year mortality remains high, likely reflecting the substantial baseline comorbidities of this population.
No takes yet. Share an insight, caveat, or question.
Supports short-term safety of closure; leaves open need for randomized trials on benefit versus observation.
Beri et al. (2019) conducted a cohort in Iatrogenic atrial septal defect after transseptal mitral valve interventions (n=17). Iatrogenic atrial septal defect closure was evaluated on 30-day survival. Iatrogenic atrial septal defect closure after transseptal mitral valve interventions was associated with 94% survival at 30 days and 71% survival at 12 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: